BioCorRx Inc
OTC:BICX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (16.1), the stock would be worth $-1.11 (374% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.9 | $0.41 |
0%
|
| Industry Average | 16.1 | $-1.11 |
-374%
|
| Country Average | 13.3 | $-0.92 |
-327%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
BioCorRx Inc
OTC:BICX
|
10m USD | -5.9 | -1.9 | |
| US |
|
HCA Healthcare Inc
NYSE:HCA
|
98.7B USD | 8.1 | 15 | |
| SA |
|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
98B SAR | 28.8 | 40.8 | |
| ZA |
N
|
Netcare Ltd
JSE:NTC
|
23.5B ZAR | 9.6 | 14 | |
| MY |
I
|
IHH Healthcare Bhd
KLSE:IHH
|
77.9B MYR | 14 | 37.1 | |
| ZA |
L
|
Life Healthcare Group Holdings Ltd
JSE:LHC
|
17.7B ZAR | 3.5 | 4.6 | |
| BR |
|
Rede D'Or Sao Luiz SA
BOVESPA:RDOR3
|
85.4B BRL | 158.6 | 18.2 | |
| US |
|
Tenet Healthcare Corp
NYSE:THC
|
15.7B USD | 4.6 | 11.5 | |
| CN |
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
102.5B CNY | 17.5 | 30.4 | |
| IN |
|
Apollo Hospitals Enterprise Ltd
NSE:APOLLOHOSP
|
1.1T INR | 32.3 | 62.1 | |
| US |
|
Ensign Group Inc
NASDAQ:ENSG
|
11B USD | 19.3 | 31.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
BioCorRx Inc
Glance View
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.
